Molecules 2011, 16
inflammatory activity after oral administration, and that 2-methyl-3-hydroxy-3,3-diphenyl-
6646
propanoic acid has greatest activity, surpassing that of ibuprofen, a standard NSAID.
Another compound, 3-hydroxy-3,3-diphenylpropanoic acid, shows activity matching that
of ibuprofen, and is non-chiral and is proven to be non-toxic. The most of investigated
compounds have interactions with P3 anchor site like COX-2 selective inhibitors. No tested
substances or ibuprofen produced any significant gastric lesions.
Keywords: β-hydroxy-β-arylpropanoic acids; Reformatsky reaction; anti-inflammatory
activity; molecular docking simulations; COX-2 selective inhibitor
1. Introduction
Cyclooxygenase (COX), also known as prostaglandin endoperoxide synthase, is a bifunctional
enzyme that catalyzes the conversion of arachidonic acid to prostaglandin (PG) H2, the immediate
precursor to prostaglandins, thromboxane and prostacyclin. The conversion of arachidonic acid into
PGH2 proceeds through two separate reactions in which two molecules of O2 are incorporated into
arachidonic acid bound in the COX site to form PGG2, which then diffuses to the peroxidase site
(POX) to undergo a two-electron reduction to form the final product PGH2. Prostaglandins (PGs) are
the lipid mediators made by most cells in the body except by red blood cells and released upon almost
any type of chemical or mechanical stimulus [1]. The two definitely known isoforms of COX, named
COX-1 and COX-2 show distinct expressions patterns and distinct biological activities. COX-1 Is
formed in many different cells to create prostaglandins that serve for basic "housekeeping" messages
throughout the body. This is a constitutively expressed protein that is responsible for the physiological
production of prostaglandins. The COX-1 variant protein, named COX-3, is sensitive to inhibition with
paracetamol [2]. COX-2 is only formed in special cells and is used for signalling both the pain and
inflammation. This isoform is also called inducible isoform of enzyme COX [3]. In inflammatory
processes COX-2 is overexpressed.
Non-steroidal anti-inflammatory drugs (NSAIDs) are COX inhibitors and prevent PG synthesis,
thus exhibiting analgesic, antipyretic and anti-inflammatory actions. However, NSAIDs have a number
of adverse effects, mainly because of their inhibition of the constitutive isoform of COX. The major
adverse effects of NSAIDs are gastrotoxic (e.g., damage of gastric mucosa, may provoke gastric
bleeding and gastroduodenal ulcers), increased bleeding tendency and delay of the birth process [1].
Nowadays, there are known two types of COX inhibitors, nonselective, i.e., both COX-1 and COX-2
inhibitors, and predominantly selective COX-2 inhibitors such as the "coxibs". Since selective COX-2
inhibitors fail to inhibit constitutive COX-1 isoform, they have no gastrointestinal adverse effects.
However, recent publications have suggested that COX-2 inhibitors, like rofecoxib and celecoxib, may
be prothrombic and increase the risk of myocardial infarction [2]. Consequently, a synthesis of new
NSAIDs, with potent anti-inflammatory, analgesic and antipyretic action, but with no adverse effects is
highly desired.
We have synthesized six β-hydroxy-β-aryl propanoic acids having none, one, or two methyl groups
at the α-position. These acids are structurally similar to COX inhibitors: p-isobutylphenyl acetic